Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908477 · ClinicalTrials.gov registry record · Phase 3
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
NCT02908477: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT02908477 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 228 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02908477, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
Study Summary
This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy. This study investigates a less intense radiation treatment following surgery that uses half the dose of radiation given over two weeks rather than six weeks. Patients will be randomly assigned to receive the less intense treatment versus the traditional treatment by coin flip. Patients are twice as likely to receive the less intense treatment during randomization.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- RADIATION Adjuvant Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2016-10-03 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908477
The ClinicalTrials.gov registry entry for NCT02908477 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT02908477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02908477 about?
NCT02908477 is a clinical study titled "Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer". This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy. This study investigates a less intense radiation treatment following surgery that uses hal...
What is the current status of trial NCT02908477?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2016-10-03. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT02908477?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Adjuvant Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02908477?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.